Telmisartan, a widely used blood pressure drug, has shown unexpected promise as a booster for cancer treatment. Preclinical research indicates that when telmisartan is combined with the PARP inhibitor olaparib, cancer cells accumulate more DNA damage and become more vulnerable to treatment, even if they do not carry the usual BRCA‑type DNA repair defects that […]
ACE‑106 (ACE‑86225106) is a highly selective PARP1 inhibitor designed to improve the therapeutic index compared with first‑generation pan‑PARP inhibitors, which broadly inhibit both PARP1 and PARP2 while causing substantial hematologic toxicity. The updated first‑in‑human data from the open‑label, dose‑escalation study show that ACE‑106 is well tolerated, with no dose‑limiting toxicities, no grade 4–5 treatment‑related adverse […]
The BRCAAway trial brings strong new data on treating metastatic castration-resistant prostate cancer, or mCRPC, in patients with specific DNA repair defects known as homologous recombination repair mutations, or HRRm. This phase 2 study tested abiraterone alone, olaparib alone, or the two drugs together as first-line therapy. It focused on patients with germline or somatic […]
Saruparib (AZD5305), a next-generation PARP1-selective inhibitor, represents a promising evolution in prostate cancer therapy, particularly for metastatic castration-sensitive disease (mCSPC), through the ongoing phase III EvoPAR-PR01 trial. Unlike first-generation PARP inhibitors (PARPi) such as olaparib that target both PARP1 and PARP2, saruparib specifically inhibits and traps PARP1 on DNA damage sites, sparing PARP2 to potentially […]
A first-in-human Phase 1/2 trial of SPR1020, a highly selective PARP1 inhibitor, dosed its inaugural patient, igniting hope for patients with advanced solid tumors harboring DNA repair deficiencies. This open-label, multicenter study employs a classic 3+3 dose-escalation design to pinpoint the recommended Phase II dose or maximum tolerated dose, transitioning seamlessly into expansion cohorts tailored […]
Copanlisib combined with rucaparib demonstrates tolerability and early signals of activity in metastatic castration-resistant prostate cancer (mCRPC), according to results from the BrUOG360 phase Ib/II trial published in late 2025. Metastatic castration-resistant prostate cancer with homologous recombination deficiency (HRD) responds to PARP inhibitors like rucaparib, but many patients develop resistance through alternative DNA repair pathways. […]
This site uses cookies. By continuing to browse the site, you are agreeing to our use of cookies.
Accept settingsHide notification onlySettingsWe may request cookies to be set on your device. We use cookies to let us know when you visit our websites, how you interact with us, to enrich your user experience, and to customize your relationship with our website.
Click on the different category headings to find out more. You can also change some of your preferences. Note that blocking some types of cookies may impact your experience on our websites and the services we are able to offer.
These cookies are strictly necessary to provide you with services available through our website and to use some of its features.
Because these cookies are strictly necessary to deliver the website, refusing them will have impact how our site functions. You always can block or delete cookies by changing your browser settings and force blocking all cookies on this website. But this will always prompt you to accept/refuse cookies when revisiting our site.
We fully respect if you want to refuse cookies but to avoid asking you again and again kindly allow us to store a cookie for that. You are free to opt out any time or opt in for other cookies to get a better experience. If you refuse cookies we will remove all set cookies in our domain.
We provide you with a list of stored cookies on your computer in our domain so you can check what we stored. Due to security reasons we are not able to show or modify cookies from other domains. You can check these in your browser security settings.
These cookies collect information that is used either in aggregate form to help us understand how our website is being used or how effective our marketing campaigns are, or to help us customize our website and application for you in order to enhance your experience.
If you do not want that we track your visit to our site you can disable tracking in your browser here:
We also use different external services like Google Webfonts, Google Maps, and external Video providers. Since these providers may collect personal data like your IP address we allow you to block them here. Please be aware that this might heavily reduce the functionality and appearance of our site. Changes will take effect once you reload the page.
Google Webfont Settings:
Google Map Settings:
Google reCaptcha Settings:
Vimeo and Youtube video embeds:
The following cookies are also needed - You can choose if you want to allow them:
You can read about our cookies and privacy settings in detail on our Privacy Policy Page.
Privacy Policy